一覧に戻る

タイトル
  • Recommended Management of Hypertensive Patients with Diabetes for Renin-Angiotensin System (RAS) Inhibitors
作成者

Bando, Hiroshi

権利情報
    • © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
主題
  • Other Hypertension
  • Other Diabetes Mellitus
  • Other Renin-Angiotensin System (RAS) Inhibitors
  • Other Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Other Angiotensin Receptor Blockers (ARB)
内容注記
Other
  • Currently, major categories of antihypertensive agents include diuretics, beta-blockers, calcium channel blockers (CCBs), renin-angiotensin system (RAS) inhibitors [angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)]. Among them, RAS (ACE inhibitors and ARB) would be recommended to be a first-line treatment when providing antihypertensive agents for hypertensive patients with diabetes, cardiovascular disease, and impaired renal function. Randomized controlled trials (RCT) of RAS inhibitors compared with other antihypertensive showed a rather lower relative risk (RR). They are all-cause death (RR - 0.95), cardiovascular death (RR - 0.84), incidence of cardiovascular disease (RR - 0.93), and incidence of renal dysfunction (RR - 0.91).
出版者Asploro
日付 Issued 2020-04-16
言語eng
資源タイプjournal article
出版タイプVoR
資源識別子 URI http://repo.lib.tokushima-u.ac.jp/114836
関連
  • isIdenticalTo DOI https://doi.org/10.36502/2020/droa.6161
収録誌情報
    • Diabetes Research : Open Access
    2(1), 4-8
ファイル
コンテンツ更新日時2020-06-11T02:56:29Z